Hospitals and Labs to earn revenues on account of Covid -19 in the recent year also
Whether or not the pandemic comes to an end in 2021, hospitals and labs will continue to earn revenues on account of Covid-19. Hospitals and diagnostic labs had been at the forefront of the fight against Covid-19 in 2020 and are looking forward to resume normal business - non-emergency treatments, elective surgeries and medical tourism - next year. Most of these had come to a grinding halt in the wake of the pandemic, hitting revenue targets. The RT-PCR tests will carry on, and the massive vaccination drive will require lakhs of antibody tests to check for immunity. One would need to do the antibody test before getting the vaccine to find out if one already has antibodies. Post vaccination, too, people would need to do the test to see if they have developed immunity. The testing technology will also be utilised for various other diseases.
Diagnostics majors point out that the pandemic has made people more aware of their health and this can be a major revenue driver in the future. At the moment, preventive tests account for less than 5 percent of the industry’s turnover. Ameera Shah, promoter and MD of Metropolis Healthcare, said that the share of preventive health check-ups in the overall portfolio is likely to increase in the coming months.
According to a report, occupancy levels in hospitals had fallen to 30-40 per cent by the end of March this year, whereas pre-Covid, they were around 65-70 per cent. This is because non-emergency treatments and elective surgeries took a backseat as people preferred not to risk a hospital visit while the pandemic was raging.
“In 2021, the recovery and development of the healthcare sector should be our top priority. We have to look for additional innovative and interactive IT platforms to accommodate more and more online consultations,” said Sandeep Budhiraja, group medical director, Max Healthcare.
Analysts at ICRA estimate that the sector will end the fiscal with a 15-20 per cent dip in revenue and about a 60 per cent fall in Ebitda. Kapil Banga, Assistant Vice- President, ICRA, said that 2021 will see growth riding back on two things - medical tourism and the pent-up demand for elective surgeries. In fact, thanks to the low base of FY21, the next fiscal would show a robust rise in revenue and Ebitda, analysts said.
Though some experts feel that greenfield expansions are likely to be put on hold, not everyone agrees with that view. Dilip Jose, MD and CEO of Manipal Hospitals, which recently acquired Columbia Asia Hospitals, said, “If one does not have a cash flow problem, greenfield expansion plans can continue in 2021. It takes 24 months or so for a greenfield set-up to come up and by then the demand would also grow.”
DE-CIX India establishes 2 new PoPs in Noida, Delhi NCR and 2
The leading carrier and data center neutral Internet Exchange (IX) operator...
India can create 1 Trillion economic value from digital econom
India has huge potential to create 1 Trillion economic value from digital e...
Salesforce Ventures invests $15 mn in tech startup Darwinbox
Salesforce Ventures has made one of its first investments in India. It has...
eScan- MicroWorld Software Services Pvt. Ltd.
Bharat Electronics Limited (BEL)